+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Graft Versus Host Disease (GVHD) - Epidemiology Forecast to 2030

  • ID: 4330796
  • Drug Pipelines
  • June 2021
  • Region: Global
  • DelveInsight
This ‘Graft-versus-host disease (GvHD) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted GvHD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

GvHD Understanding


Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host's tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplantation).The two main types of GvHD are acute GvHD and chronic GvHD.

Acute GvHD (aGvHD) might occur once the donor's cells have engrafted in the transplant recipient and have been observed to affect skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant. Acute GvHD is staged and graded (grade 0-IV) by the number and extent of organ involvement (skin, liver, and gastrointestinal). That staging is then used to determine the overall grade of the patient. Usually, patients with grade III-IV acute GvHD have a much worse outcome than those with grade I-II GvHD. The treatment depends on the grade of patient's GvHD. Chronic GvHD (cGvHD) usually develops later than 100 days after the transplant, and it might occur in the skin, liver, mouth, lungs, gastrointestinal tract, neuromuscular system, or genitourinary tract. Its diagnosis is based on manifestations and not timing. The doctor assesses the GvHD by looking at the number of organs involved and severity. Depending on this, they give it one of the following grades: mild, moderate and severe chronic GvHD. Patients who have an increased risk of developing chronic GvHD are: those who have received stem cells/bone marrow from an HLA mismatched related donor or from an HLA matched unrelated donor, use of peripheral blood stem cells (PBSCs), patients who may have already experienced acute GvHD, older transplant recipients and conditioning regimen.

The diagnosis of aGvHD is based wholly on clinical criteria that can be established by biopsy of one of the three target organs. Additionally, laboratory data and/or imaging studies are also useful tests in the diagnostic approach to GvHD. In cGvHD, some symptoms might be very ambiguous, which might make the diagnosis possible only after other causes are excluded. Some tests which are useful in diagnosis are biopsy (liver and skin), endoscopy, X-rays and scans, lung function tests and blood tests

Epidemiology Perspective


The GvHD epidemiology division provides the insights about historical and current GvHD patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.The disease epidemiology covered in the report provides historical as well as forecasted GVHD epidemiology [segmented as Total Hematopoietic stem-cell transplantation (HSCT), Total Allogeneic Transplant cases, Total GvHD cases by Types (Acute and Chronic), Total Incident cases of aGvHD by Grading and organ Involvement, Total Incident cases of cGvHD by Grading and organ involvement, Total Treated patients of GvHD and Mortality adjusted GvHD treated patients] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Country Wise- GVHD Epidemiology


Key Findings

  • In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
  • GvHD is categorized into two types: aGvHD and cGvHD. In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021-2030. Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
  • In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per the analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020
  • The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.

Scope of the Report

  • The GvHD report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
  • The GvHD Report and Model provide an overview of the risk factors and global trends of GVHD in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of GvHD in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of GvHD.
  • The report provides the segmentation of the GVHD epidemiology by types (Acute and Chronic) in the 7MM.
  • The report provides the segmentation of the aGVHD epidemiology by Grading and organ Involvement in the 7MM.
  • The report provides the segmentation of the cGVHD epidemiology by Grading and organ involvement in the 7MM.
  • The report provides the segmentation of the GVHD epidemiology by line-wise treated patients in the 7MM.
  • The report provides the segmentation of the GVHD epidemiology by Mortality adjusted treated patients in the 7MM.

Report Highlights

  • 10-Year Forecast of GVHD epidemiology
  • 7MM Coverage
  • Epidemiology Segmentation

KOL-Views


The publisher interviews, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over GVHD scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GvHD?
  • What are the key findings pertaining to the GvHD epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of patients of GvHD across the 7MM during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of GvHD?

Reasons to Buy


The GvHD Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global GvHD market
  • Quantify patient populations in the global GVHD market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for GvHD therapeutics in each of the markets covered
  • Understand the magnitude of the GvHD population by its severity
  • The GvHD epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The GvHD Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Note: Product cover images may vary from those shown
1. Key Insights

2. Report Introduction

3. Executive Summary of GvHD

4. Epidemiology Forecast Flow

5. Disease Background and Overview
5.1. Introduction
5.2. Types of GvHD
5.3. Acute GvHD
5.3.1. Staging of acute GvHD
5.3.2. Grading of acute
5.3.3. Signs and symptoms of acute GvHD
5.3.4. Risk factors for acute GvHD
5.3.5. Pathophysiology of acute GvHD
5.4. Chronic GvHD
5.4.1. Classification of chronic GvHD
5.4.2. Signs and symptoms of chronic GvHD
5.4.3. Risk factors for chronic GvHD
5.4.4. Pathophysiology of chronic GvHD
5.5. Diagnosis of GvHD
5.5.1. Differential diagnosis of GvHD
5.5.2. Diagnostic algorithm
5.5.3. European Society for Blood and Marrow Transplantation (EBMT and guidance for GvHD assessment
5.5.4. Comparison of the different guidelines available for chronic GvHD assessment: Overall severity staging

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale
6.3. Epidemiology Scenario (7MM)
6.3.1. Total Hematopoietic stem-cell transplantation (HSCT) in the 7MM
6.3.2. Total Allogeneic Transplant cases in the 7MM
6.3.3. Total GvHD cases by Types (Acute and Chronic) in the 7MM
6.3.4. Total Incident cases of aGvHD by grading and organ Involvement in the 7MM
6.3.5. Total Incident cases of cGvHD by Grading and organ involvement in the 7MM
6.3.6. Total Treated patients of GvHD in the 7MM
6.3.7. Mortality adjusted GvHD treated patients in the 7MM
6.4. The United States
6.4.1. Total GvHD cases by Types (Acute and Chronic) in the US
6.4.2. Total Incident cases of aGvHD by Grading and organ Involvement in the US
6.4.3. Total Incident cases of cGvHD by Grading and organ involvement in the US
6.4.4. Total Treated patients of GvHD in the US
6.4.5. Mortality adjusted GvHD treated patients in the US
6.5. EU-5 Epidemiology
6.6. Germany
6.6.1. Total GvHD cases by Types (Acute and Chronic) in Germany
6.6.2. Total Incident cases of aGvHD by Grading and organ Involvement in Germany
6.6.3. Total Incident cases of cGvHD by Grading and organ involvement in Germany
6.6.4. Total Treated patients of GvHD in Germany
6.6.5. Mortality adjusted GvHD treated patients in Germany
6.7. France
6.7.1. Total GvHD cases by Types (Acute and Chronic) in France
6.7.2. Total Incident cases of aGvHD by Grading and organ Involvement in France
6.7.3. Total Incident cases of cGvHD by Grading and organ involvement in France
6.7.4. Total Treated patients of GvHD in France
6.7.5. Mortality adjusted GvHD treated patients in France
6.8. Italy
6.8.1. Total GvHD cases by Types (Acute and Chronic) in Italy
6.8.2. Total Incident cases of aGvHD by Grading and organ Involvement in Italy
6.8.3. Total Incident cases of cGvHD by Grading and organ involvement in Italy
6.8.4. Total Treated patients of GvHD in Italy
6.8.5. Mortality adjusted GvHD treated patients in Italy
6.9. Spain
6.9.1. Total GvHD cases by Types (Acute and Chronic) in Spain
6.9.2. Total Incident cases of aGvHD by Grading and organ Involvement in Spain
6.9.3. Total Incident cases of cGvHD by Grading and organ involvement in Spain
6.9.4. Total Treated patients of GvHD in Spain
6.9.5. Mortality adjusted GvHD treated patients in Spain
6.10. The United Kingdom
6.10.1.Total GvHD cases by Types (Acute and Chronic) in the UK
6.10.2.Total Incident cases of aGvHD by Grading and organ Involvement in the UK
6.10.3.Total Incident cases of cGvHD by Grading and organ involvement in the UK
6.10.4.Total Treated patients of GvHD in the UK
6.10.5.Mortality adjusted GvHD treated patients in the UK
6.11. Japan Epidemiology
6.11.1.Total GvHD cases by Types (Acute and Chronic) in Japan
6.11.2.Total Incident cases of aGvHD by Grading and organ Involvement in Japan
6.11.3.Total Incident cases of cGvHD by Grading and organ involvement in Japan
6.11.4.Total Treated patients of GvHD in Japan
6.11.5.Mortality adjusted GvHD treated patients in Japan

7. Appendix
7.1. Bibliography
7.2. Report Methodology

8. Publisher Capabilities

9. Disclaimer

10. About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll